South Plainfield, NJ-based PTC Therapeutics entered into an exclusive licensing agreement with AstraZeneca (NYSE: [[ticker:AZN]]) for PTC’s technology, called GEMS (gene expression modulation by small molecules), according to a press release. The GEMS technology is designed to identify compounds that target particular regions of messenger RNA molecules. The collaboration is geared towards discovering new remedies for cancer and other diseases. The agreement includes an undisclosed up-front payment, plus future payments that will hinge on research, development, regulatory and commercial milestones.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
